| Authors: |
Lui GYL; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: glui@fredhutch.org., Shaw R; SEngine Precision Medicine, Seattle, WA, USA; Cure First, Seattle, WA, USA., Schaub FX; SEngine Precision Medicine, Seattle, WA, USA; Cure First, Seattle, WA, USA., Stork IN; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Gurley KE; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Bridgwater C; SEngine Precision Medicine, Seattle, WA, USA., Diaz RL; SEngine Precision Medicine, Seattle, WA, USA., Rosati R; SEngine Precision Medicine, Seattle, WA, USA; Cure First, Seattle, WA, USA., Swan HA; SEngine Precision Medicine, Seattle, WA, USA., Ince TA; Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA & New York Presbyterian-Brooklyn Methodist Hospital, Brooklyn, NY, USA., Harding TC; Clovis Oncology, Boulder, CO, USA., Gadi VK; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Goff BA; Department of Obstetrics & Gynecology, University of Washington, Seattle, WA, USA., Kemp CJ; Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Swisher EM; Department of Obstetrics & Gynecology, University of Washington, Seattle, WA, USA., Grandori C; SEngine Precision Medicine, Seattle, WA, USA; Cure First, Seattle, WA, USA. Electronic address: cgrandori@senginemedicine.com. |
